Anne-Marie Masquelier joins Cegedim Strategic Data

Takes role of global medical research director

Cegedim Strategic Data (CSD), a French provider of integrated healthcare research, has appointed Dr Anne-Marie Masquelier as global medical research director of its medical research CRO activities worldwide.

Masquelier is a medical doctor MD with a specialisation in endocrinology and holds an MBA in marketing/management. She started her career as a medical practitioner before moving to the healthcare industry where she held various management positions in pharmaceutical, CRO and biotech companies. Most recently she was general manager of Genethon.

Masquelier will manage CSD’s established medical research teams in France, Germany, Italy, Spain and UK, China, Japan and the US. She will continue the expansion of this activity in all of the 39 countries where CSD is present.

You may also like

Regulatory

Power to the patient: The value of longitudinal data

Steve Bradley, Group Managing Director, Cegedim UK, outlines how data holds the key to better patient care
Finance

Cegedim Dendrite forms partnership with TAKE Solutions

Arrangement will enable Cegedim to expand its presence in India
Finance

Cegedim expands business in Switzerland

Acquires Swiss CRM and Direct Marketing businesses of IMS Health
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Subscribe now